Skip to content
Search

Latest Stories

LG chairman apologises over gas leak, fire

LG Group chairman Koo Gwang-mo apologised Wednesday (20) over two fatal accidents at LG Chem facilities in the past two weeks, reports said, including a gas leak in India that killed 12 people.

LG Group is the fourth-biggest of the chaebols, the family-controlled conglomerates that dominate business in South Korea, the world's 12th-largest economy.


LG Chem, the group's key subsidiary and South Korea's largest chemical company, is reeling from the deadly gas leak at its LG Polymers India subsidiary, which left 12 residents dead and saw more than 1,000 hospitalised.

On Wednesday, a fire broke out at LG Chem's plant in Seosan, around 120 kilometres south of Seoul, killing a researcher and injuring two workers.

"I express my deep condolences and consolation to victims and their families," Koo said at the Seosan plant, according to Yonhap news agency.

"I am very sorry for causing concern to many people," Koo added, noting that management felt "heavy responsibility" for the safety accidents.

LG Chem produces petrochemicals, plastic resins, and engineering plastics, and has plants across South Korea and around the world, from the United States and Brazil to China and Australia.

The company also manufactures industrial and electronic materials and has emerged as one of the top battery suppliers for hybrid and electric cars, with customers including Mercedes Benz, Volvo, Volkswagen, and BMW.

LG Chem recorded sales of $24.5 billion last year and an operating profit of $800 million, according to its website.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less